These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 15224127)

  • 21. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
    Corbin JD; Beasley A; Blount MA; Francis SH
    Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
    Park K; Moreland RB; Goldstein I; Atala A; Traish A
    Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
    Hallén K; Wiklund NP; Gustafsson LE
    Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
    Kalsi JS; Kell PD; Cellek S; Ralph DJ
    Int J Impot Res; 2004 Apr; 16(2):195-200. PubMed ID: 14961060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
    Rosen RC; Kostis JB
    Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
    Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
    Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion.
    Sopory S; Kaur T; Visweswariah SS
    Cell Signal; 2004 Jun; 16(6):681-92. PubMed ID: 15093609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
    Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
    Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
    Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F; Longhurst PA; White MD
    BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum.
    Gur S; Kadowitz PJ; Trost L; Hellstrom WJ
    J Urol; 2007 Oct; 178(4 Pt 1):1543-8. PubMed ID: 17707054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.
    Moreland RB; Goldstein I; Traish A
    Life Sci; 1998; 62(20):PL 309-18. PubMed ID: 9600334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitric oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells.
    Cawley SM; Sawyer CL; Brunelle KF; van der Vliet A; Dostmann WR
    Cell Signal; 2007 May; 19(5):1023-33. PubMed ID: 17207606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary on apomorphine versus sildenafil for erectile dysfunction.
    Carson CC
    J Urol; 2008 May; 179(5 Suppl):S95-6. PubMed ID: 18405768
    [No Abstract]   [Full Text] [Related]  

  • 36. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
    Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
    Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro.
    Chuang AT; Strauss JD; Murphy RA; Steers WD
    J Urol; 1998 Jul; 160(1):257-61. PubMed ID: 9628660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.
    Gopal VK; Francis SH; Corbin JD
    Eur J Biochem; 2001 Jun; 268(11):3304-12. PubMed ID: 11389733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.
    Yuan Z; Hein TW; Rosa RH; Kuo L
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):720-5. PubMed ID: 18235020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.